Atrial fibrillation in old age: current treatment options
https://doi.org/10.21886/2712-8156-2022-3-1-7-14
Abstract
In older age, patients with atrial fibrillation (AF) have a high risk of stroke, bleeding, and death, but such patients have been underrepresented in randomized clinical trials. A search and analysis of 4 176 literature sources from the MEDLINE/ PubMed and eLIBRARY databases was carried out for the keywords «atrial fibrillation», «old age», «older», «elderly». The review includes the most important studies reflecting the current understanding of risk factors for development, complications and treatment of AF in old age. The results of therapy to control the ventricular rate, to control sinus rhythm in AF with drugs and catheter ablation are discussed. The data of studies on the prevention of thromboembolic complications in patients with AF by the use of anticoagulants and implantable devices are considered.
About the Author
S. G. Kanorskii
Kuban State Medical University
Russian Federation
Russian Federation
Sergey G. Kanorskii — Dr. Sci. (Med.), Professor, Head of the Department of Internal Medicine № 2 of the Faculty of Advanced Training and Professional Retraining, Kuban State Medical University.
Krasnodar.
References
1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-e743. DOI: 10.1161/CIR.0000000000000950.
2. Wang L, Ze F, Li J, Mi L, Han B, Niu H, et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. Heart. 2021;107(11):881-887. DOI: 10.1136/heartjnl-2020-317656.
3. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20(12):1929-1935. DOI: 10.1093/europace/euy117.
4. Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. Eur Heart J. 2021;42(46):4759-4768. DOI: 10.1093/eurheartj/ehab315.
5. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015;169(5):647-654.e2. DOI: 10.1016/j.ahj.2014.12.024.
6. Soliman EZ, Rahman AF, Zhang ZM, Rodriguez CJ, Chang TI, Bates JT, et al. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation. Hypertension. 2020;75(6):1491-1496. DOI: 10.1161/HYPERTENSIONAHA.120.14766.
7. Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9. DOI: 10.1186/s12933-019-0983-1.
8. Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19(1):130. DOI: 10.1186/s12933-020-01105-5.
9. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118(8):800-807. DOI: 10.1161/CIRCULATIONAHA.108.785626.
10. Proietti M, Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, et al. Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace. 2017;19(4):535-543. DOI: 10.1093/europace/euw150.
11. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, JoglarJA,etal.LifestyleandRiskFactorModificationforReduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020;141(16):e750-e772. DOI:10.1161/CIR.0000000000000748.
12. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555-1566. DOI: 10.1177/2047487317715769.
13. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. DOI: 10.1161/JAHA.112.000102.
14. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016;133(5):484-492. DOI: 10.1161/CIRCULATIONAHA.115.018614.
15. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. DOI:10.1056/NEJMoa1409077.
16. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225. DOI: 10.1093/eurheartj/ehi115.
17. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12(9):1386-1398. DOI: 10.2215/CJN.01860217.
18. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. DOI:10.1056/NEJMoa2019422.
19. Depoorter L, Sels L, Deschodt M, Van Grootven B, Van der Linden L, Tournoy J. Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis. Drugs Aging. 2020;37(1):19-26. DOI: 10.1007/s40266-019-00722-4.
20. Paciullo F, Proietti M, Bianconi V, Nobili A, Pirro M, Mannucci PM, et al. Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs Aging. 2018;35(4):365-373. DOI: 10.1007/s40266-018-0532-8.
21. Dalgaard F, Pallisgaard JL, Numé AK, Lindhardt TB, Gislason GH, Torp-Pedersen C, et al. Rate or Rhythm Control in Older Atrial Fibrillation Patients: Risk of Fall-Related Injuries and Syncope. J Am Geriatr Soc. 2019;67(10):2023-2030. DOI: 10.1111/jgs.16062.
22. Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. Am J Cardiol. 2019;123(1):69-74. DOI: 10.1016/j.amjcard.2018.09.036.
23. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018;71(10):1063-1074. DOI: 10.1016/j.jacc.2017.12.060.
24. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020;324(24):2497-2508. DOI: 10.1001/jama.2020.23138.
25. Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю., Голицын С. П., Голухова Е. З., Горев М. В., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. DOI:10.15829/1560-4071-2021-4594.
26. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612.
27. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-1274. DOI: 10.1001/jama.2019.0693.
28. Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, et al. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results from the CABANA Trial. Circulation. 2022;145(11):796-864. DOI: 10.1161/CIRCULATIONAHA.121.055297.
29. Nademanee K, Amnueypol M, Lee F, Drew CM, Suwannasri W, Schwab MC, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm. 2015;12(1):44-51. DOI: 10.1016/j.hrthm.2014.09.049.
30. Piccini JP, Sinner MF, Greiner MA, Hammill BG, Fontes JD, Daubert JP, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012;126(18):2200-2207. DOI: 10.1161/CIRCULATIONAHA.112.109330.
31. Ikenouchi T, Nitta J, Nitta G, Kato S, Iwasaki T, Murata K, et al. Propensity-matched comparison of cryoballoon and radiofrequency ablation for atrial fibrillation in elderly patients. Heart Rhythm. 2019;16(6):838-845. DOI: 10.1016/j.hrthm.2018.12.019.
32. Vermeersch G, Abugattas JP, Varnavas V, De Cocker J, Schwagten B, Sieira J, et al. Efficacy and safety of the second-generation cryoballoon ablation for the treatment of persistent atrial fibrillation in elderly patients. J Arrhythm. 2021;37(3):626-634. DOI: 10.1002/joa3.12531.
33. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021;42(46):4731-4739. DOI: 10.1093/eurheartj/ehab569.
34. Zink MD, Mischke KG, Keszei AP, Rummey C, Freedman B, Neumann G, et al. Screen-detected atrial fibrillation predicts mortality in elderly subjects. Europace. 2021;23(1):29-38. DOI: 10.1093/europace/euaa190.
35. Benjamin EJ, Go AS, Desvigne-Nickens P, Anderson CD, Casadei B, Chen LY, et al. Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2021;143(4):372-388. DOI: 10.1161/CIRCULATIONAHA.120.047633.
36. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomized controlled trial. Lancet. 2021;398(10310):1507-1516. DOI:10.1016/S0140-6736(21)01698-6.
37. Gebreyohannes EA, Salter S, Chalmers L, Bereznicki L, Lee K. Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence. Am J Cardiovasc Drugs. 2021;21(4):419-433. DOI: 10.1007/s40256-020-00457-3.
38. Ekerstad N, Karlsson T, Söderqvist S, Karlson BW. Hospitalized frail elderly patients - atrial fibrillation, anticoagulation and 12 months’ outcomes. Clin Interv Aging. 2018;13:749-756. DOI:10.2147/CIA.S159373.
39. Lane DA, Lip GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. Eur Heart J Suppl. 2020;22(Suppl O):O14-O27. DOI: 10.1093/eurheartj/suaa178.
40. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011.
41. Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am J Med. 2014;127(10):979-986.e2. DOI: 10.1016/j.amjmed.2014.05.003.
42. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46(1):143-150. DOI: 10.1161/STROKEAHA.114.007199.
43. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0.
44. Alcusky M, Tjia J, McManus DD, Hume AL, Fisher M, Lapane KL. Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents. J Gen Intern Med. 2020;35(8):2329-2337. DOI: 10.1007/s11606-020-05777-3.
45. Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One. 2019;14(3):e0213614. DOI: 10.1371/journal.pone.0213614.
46. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age. Am J Cardiol. 2019;123(12):2051-2057. DOI: 10.1016/j.amjcard.2019.02.060.
47. Wong JM, Maddox TM, Kennedy K, Shaw RE. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence Registry). Am J Cardiol. 2020;125(10):1500-1507. DOI: 10.1016/j.amjcard.2020.02.028.
48. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation: A Cohort Study. Ann Intern Med. 2021;174(9):1214-1223. DOI:10.7326/M20-7141.
49. Hanon O, Vidal JS, Pisica-Donose G, Orvoën G, David JP, Chaussade E, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376-1382. DOI:10.1136/heartjnl-2020-317923.
50. Lau WCY, Cheung CL, Man KKC, Chan EW, Sing CW, Lip GYH, et al. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. Ann Intern Med. 2020;173(1):1-9. DOI: 10.7326/M19-3671.
51. Proietti M, Recchia A, Riva E, Lucca U, Tettamanti M, Mannucci PM, et al. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. Eur J Intern Med. 2017;46:6-10. DOI: 10.1016/j.ejim.2017.08.010.
52. Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, et al. Comparing Warfarinand4DirectOralAnticoagulantsfortheRiskofDementia in Patients With Atrial Fibrillation. Stroke. 2021;52(11):3459-3468. DOI: 10.1161/STROKEAHA.120.033338.
53. Hallinen T, Soini E, Asseburg C, Linna M, Eloranta P, Sintonen S, et al. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. Clinicoecon Outcomes Res. 2021;13:745-755. DOI: 10.2147/CEOR.S317078.
54. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. J Manag Care Spec Pharm. 2018;24(9):911-920. DOI: 10.18553/jmcp.2018.24.9.911.
55. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. DOI: 10.1016/j.jacc.2014.04.029.
56. Nasasra AE, Brachmann J, Lewalter T, Akin I, Sievert H, Nienaber CA, et al. Comparison in Patients < 75 Years of Age - Versus - Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry). Am J Cardiol. 2020;136:81-86. DOI: 10.1016/j.amjcard.2020.09.017.
57. Yu J, Chen H, Post F, Muenzel M, Keil T, Hou CR, et al. Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years. Heart Vessels. 2019;34(11):1858-1865. DOI: 10.1007/s00380-019-01428-8.
58. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2022;79(1):1-14. DOI: 10.1016/j.jacc.2021.10.023.
Review
For citations:
Kanorskii S.G. Atrial fibrillation in old age: current treatment options. South Russian Journal of Therapeutic Practice. 2022;3(1):7-14. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-1-7-14
Views:
2253
Email this article 